Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Principal Investigator
Co-Principal Investigator
-
-
Mitochon Pharmaceuticals -
Mitochon Pharmaceuticals
Project Goals
This study aims to test the safety and efficacy of a mitochondrial stabilizing drug, MP201. Traumatic brain injuries, especially when repetitive, can lead to oxidative stress and mitochondrial dysfunction that can contribute to dementia. MP201 has been shown to be therapeutically effective in multiple animal models and clinical indications and will be used for a full Investigational New Drug-enabling toxicology package with the FDA.
Project Summary
This proposal will be one of the first projects to examine mitochondrial function and treatment after mild traumatic brain injury. This project will extend an innovative fractionated mitochondrial magnetic separation technique for use in rat brain tissue. This project will stimulate research to move a promising drug MP201 into clinical trials.This study will produce scientific data in an understudied area of mitochondrial dysfunction following mild TBI as a direct benefit to the research field. The project will also generate potential of a drug candidate that could be used in clinical trials for TBI. An effective drug would greatly benefit those suffering from TBI and caregivers alike.
Publications
First published on: December 06, 2022
Last modified on: November 24, 2024